Final hours! Save up to 55% OFF InvestingProCLAIM SALE

Reckitt to sell China baby formula business for $2.2 billion

Published 06/05/2021, 03:30 PM
Updated 06/07/2021, 01:50 AM
© Reuters. FILE PHOTO: Mead Johnson's product Enfamil baby formula are displayed on a store shelf in New York City, U.S., February 10, 2017. REUTERS/Brendan McDermid/File Photo
RKT
-

(This June 5 story fixes typographical error in seventh paragraph)

By Siddharth Cavale

(Reuters) - British consumer goods maker Reckitt Benckiser Group Plc (LON:RKT) said on Saturday it was selling its infant formula and child nutrition (IFCN) business in China to investment firm Primavera Capital Group for an enterprise value of $2.2 billion.

The Lysol disinfectant and Dettol soap maker will retain an 8% stake in the IFCN China unit and anticipates net cash proceeds from the sale to be about $1.3 billion, it said in an emailed statement.

Reckitt expects to incur a net loss of 2.5 billion pounds ($3.5 billion) on the disposal, mainly due to the re-measurement of goodwill and intangible assets, it said.

Reuters in March reported that the Slough, England-based company was considering the sale of the business.

The sale closes a strategic review of IFCN China launched in February as a result of sluggish sales caused by intense competition from local Chinese baby formula brands and slowing birth rates in China.

Reckitt executives have also attributed Hong Kong border closures during the COVID-19 pandemic as weighing on the business, which it acquired as part of its $16.6 billion purchase of U.S.-based Mead Johnson in 2017.

In the same sector, French dairy group Danone sold its 9.8% stake in China Mengniu Dairy in May for about 1.6 billion euros.

Reckitt's Greater China infant formula business represents 6% of group sales, which were almost 14 billion pounds ($19.82 billion) in 2020, up 11.8% year-on-year.

On Saturday, Reckitt said the deal included the sale of its manufacturing plants at Nijmegen in the Netherlands, and in Guangzhou, China, and a royalty-free perpetual and exclusive license of the Mead Johnson and Enfa family of brands in China.

© Reuters. FILE PHOTO: Mead Johnson's product Enfamil baby formula are displayed on a store shelf in New York City, U.S., February 10, 2017. REUTERS/Brendan McDermid/File Photo

After the deal's close, expected in the second half of 2021, Reckitt will own and operate the Mead Johnson and the Enfinitas, Enfamil and Enfagrow brands in the rest of the world.

($1 = 0.7065 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.